Santhera Pharmaceuticals
Clinical trials sponsored by Santhera Pharmaceuticals, explained in plain language.
A specialty pharmaceutical company focused on treatments for rare neuromuscular and pulmonary diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New steroid hope for duchenne boys: safer muscle treatment?
Disease control CompletedThis study tested a drug called vamorolone in 54 boys with Duchenne muscular dystrophy, aged 2 to under 4 years and 7 to under 18 years. The goal was to check safety and how the body processes the drug over 12 weeks. Researchers hope vamorolone may help control the disease with f…
Phase: PHASE2 • Sponsor: Santhera Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Healthy volunteers help uncover Vamorolone's enzyme effects
Knowledge-focused CompletedThis study looked at how a medicine called vamorolone affects a key liver enzyme (CYP3A4) that processes many drugs. Eighteen healthy adults took a single dose of midazolam before and after 14 days of vamorolone to see if vamorolone changed how midazolam was handled. The results …
Phase: PHASE1 • Sponsor: Santhera Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Early study checks if experimental drug vamorolone affects Body's salt balance
Knowledge-focused CompletedThis completed Phase 1 trial tested whether the experimental drug vamorolone can block the mineralocorticoid receptor, which helps control salt and water balance in the body. Thirty healthy men received a single dose of vamorolone, a positive control drug (eplerenone), or no acti…
Phase: PHASE1 • Sponsor: Santhera Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:25 UTC